Antares Pharma (NASDAQ:ATRS) reported Q4 2017 earnings this Morning, coming in at ($0.02) per share, beating Wall Street’s estimates of ($0.03) per Share. Revenue for the quarter came in at $14.00 million missing the streets estimates of $15.44 million Recent Insider Trading for Antares Pharma (NASDAQ:ATRS)
- On 10/9/2017 Leonard S Jacob, Director, sold 230,000 with an average share price of $4.05 per share and the total transaction amounting to $931,500.00.
- On 10/3/2017 Thomas J Garrity, Director, sold 30,000 with an average share price of $3.50 per share and the total transaction amounting to $105,000.00.
- On 6/9/2017 Fred M Powell, Insider, bought 130,000 with an average share price of $2.79 per share and the total transaction amounting to $362,700.00.
- On 4/5/2017 Robert F Apple, CEO, sold 40,000 with an average share price of $3.00 per share and the total transaction amounting to $120,000.00.
- On 4/4/2017 Leonard S Jacob, Director, sold 41,762 with an average share price of $2.89 per share and the total transaction amounting to $120,692.18.
- On 4/4/2017 Robert F Apple, CEO, sold 37,000 with an average share price of $3.00 per share and the total transaction amounting to $111,000.00.
Recent Trading for Antares Pharma (NASDAQ:ATRS) Shares of Antares Pharma closed the previous trading session at 2.64 down -0.14 5.04% with 2.6500000953674316 shares trading hands.